Abliva Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • ABLI

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.04
  • (As of Friday Closing)

Abliva General Information

Description

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.

Contact Information

Website
www.abliva.com
Formerly Known As
NeuroVive Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Scheeletorget 1
  • 223 81 Lund
  • Sweden
+46 046-275
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
STO
Corporate Office
  • Scheeletorget 1
  • 223 81 Lund
  • Sweden
+46 046-275

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abliva Stock Performance

As of 14-Feb-2025, Abliva’s stock price is $0.04. Its current market cap is $67.5M with 1.61B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.04 $0.04 $0.01 - $0.04 $67.5M 1.61B 6.89M

Abliva Financials Summary

As of 30-Sep-2024, Abliva has a trailing 12-month revenue of $13K.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 22,107 20,584 11,477 19,426
Revenue 13 13 3 18
EBITDA (8,335) (8,908) (7,914) (14,069)
Net Income (8,411) (8,986) (8,404) (14,380)
Total Assets 9,599 8,755 17,622 6,510
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Abliva Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Abliva‘s full profile, request access.

Request a free trial

Abliva Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of
Pharmaceuticals
Lund, Sweden
6 As of 2024

Framingham, MA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Abliva Competitors (34)

One of Abliva’s 34 competitors is Xenetic Bioscience, a Corporation company based in Framingham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xenetic Bioscience Corporation Framingham, MA
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
Agios Pharmaceuticals Formerly VC-backed Cambridge, MA
Genfit Formerly VC-backed Loos, France
Mission Therapeutics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 34 competitors. Get the full list »

Abliva Patents

Abliva Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022277623-A1 Kl1333 for use in medicine Pending 19-May-2021
CA-3218015-A1 Kl1333 for use in medicine Pending 19-May-2021
EP-4340831-A1 Kl1333 for use in medicine Pending 19-May-2021
US-20240238255-A1 Kl1333 for use in medicine Pending 19-May-2021
US-11565998-B2 Succinate prodrug, compositions containing the succinate prodrug and uses thereof Active 19-Jun-2019 C07C327/30
To view Abliva’s complete patent history, request access »

Abliva Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Abliva Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Abliva‘s full profile, request access.

Request a free trial

Abliva Investments & Acquisitions (2)

Abliva’s most recent deal was a Early Stage VC with Isomerase for . The deal was made on 15-Aug-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Isomerase 15-Aug-2016 Early Stage VC Other Pharmaceuticals and Biotechnology
Biotica Technology 11-Mar-2013 Merger/Acquisition Biotechnology
To view Abliva’s complete investments and acquisitions history, request access »

Abliva ESG

Risk Overview

Risk Rating

Updated February, 01, 2024

29.22 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Abliva’s complete esg history, request access »

Abliva FAQs

  • When was Abliva founded?

    Abliva was founded in 2000.

  • Where is Abliva headquartered?

    Abliva is headquartered in Lund, Sweden.

  • What is the size of Abliva?

    Abliva has 6 total employees.

  • What industry is Abliva in?

    Abliva’s primary industry is Pharmaceuticals.

  • Is Abliva a private or public company?

    Abliva is a Public company.

  • What is Abliva’s stock symbol?

    The ticker symbol for Abliva is ABLI.

  • What is the current stock price of Abliva?

    As of 14-Feb-2025 the stock price of Abliva is $0.04.

  • What is the current market cap of Abliva?

    The current market capitalization of Abliva is $67.5M.

  • What is Abliva’s current revenue?

    The trailing twelve month revenue for Abliva is $13K.

  • Who are Abliva’s competitors?

    Xenetic Bioscience, ACADIA Pharmaceuticals, Agios Pharmaceuticals, Genfit, and Mission Therapeutics are some of the 34 competitors of Abliva.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »